|
|
Volumn 12, Issue 1, 2015, Pages 1-
|
|
Skin cancer: Golden age of melanoma therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE INHIBITOR;
DABRAFENIB;
DACARBAZINE;
IPILIMUMAB;
MITOGEN ACTIVATED PROTEIN KINASE;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
NIVOLUMAB;
TRAMETINIB;
VEMURAFENIB;
ANTINEOPLASTIC AGENT;
B RAF KINASE;
MONOCLONAL ANTIBODY;
PROGRAMMED DEATH 1 RECEPTOR;
BRAF GENE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
ENZYME ACTIVATION;
HUMAN;
MELANOMA;
METASTATIC MELANOMA;
MONOTHERAPY;
MUTATIONAL ANALYSIS;
NOTE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SURVIVAL RATE;
TREATMENT DURATION;
TREATMENT RESPONSE;
ANTAGONISTS AND INHIBITORS;
CELL TRANSFORMATION;
CHEMICALLY INDUCED;
FEMALE;
MALE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CELL TRANSFORMATION, NEOPLASTIC;
DACARBAZINE;
FEMALE;
HUMANS;
MALE;
MELANOMA;
PROGRAMMED CELL DEATH 1 RECEPTOR;
PROTO-ONCOGENE PROTEINS B-RAF;
|
|
EID: 84927176967
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2014.219 Document Type: Note |
|
Times cited : (11)
|
|
References (3)
|
